Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the franchise economics that justify a re-rate are intact on the income statement, but management's own credibility broke 84 days after setting the FY26 guide and the stacked-LOE window still has three years to run. The market is paying 13.2x earnings and 9.4x EV/EBITDA for an asset that just printed a record 37.5% operating margin and 25.6% ROIC, and the strongest single argument against ownership is not that those numbers are fake but that they are about to start eroding under simultaneous attacks on four of the top five products. The tension that matters most is the read on Q1 FY26's −11% U.S. companion-animal organic print: the bull treats it as a discrete Convenia/Cerenia LOE shock, the bear treats it as the first visible quarter of a multi-year compounding decay. Two clean prints — Q2 and Q3 FY26 U.S. companion-animal organic returning to flat-or-positive — would convert this into a high-conviction long. A second consecutive negative print, or any further guidance cut, would flip the verdict and validate the bear's $60 downside scenario.

Bull Case

Bull's price target is $125, set via 18x normalized EPS of ~$6.95 (mid of revised FY26 guidance, before buyback accretion) and cross-checked at ~$130 via $2.28B FY25 FCF capitalized at a 4.5% yield. Timeline: 12–18 months, contingent on Q2/Q3 FY26 U.S. companion-animal organic stabilizing ex-LOE and the FY27 Librela/Apoquel comparable bridging clean of the Convenia/Cerenia drag. Disconfirming signal: operating margin breaking below 35% OR U.S. companion-animal organic growth remaining negative through Q3 FY26 — either would mean the moat is compressing, not just digesting a discrete LOE event.

Bear Case

Bear's downside scenario is $60 (≈24% below the May 20 2026 close of $79.71), set via 10x through-cycle EV/EBITDA on a normalized EBITDA of $3.2B (FY25 $4.03B haircut for cumulative LOE drag and competitive defense cost), cross-checked via 14x P/FCF on $1.8B normalized FCF (FY25 $2.28B haircut ~$500M). Timeline: 12–18 months, long enough to absorb Q2/Q3 FY26 prints, the 2H 2026 Bravecto Quantum US launch curve, and the first full year of Apoquel formulation generic pressure. Cover signal: U.S. companion-animal organic growth returns positive for two consecutive quarters AND Simparica Trio U.S. dose-equivalent growth stays positive through 2H 2026 with the Bravecto Quantum launch curve fully in the data.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. The bull case carries slightly more weight because the income statement — record 37.5% operating margin, 71.8% gross margin, 24.1% FCF margin, 13.2x P/E — is observable now, while the bear's worst-case requires three more years of stacked-LOE compounding to fully materialize; said differently, the bull's edge is in price, the bear's edge is in time. The single most important tension is whether Q1 FY26's −11% U.S. companion-animal organic print is a discrete Convenia/Cerenia LOE shock or the first visible quarter of structural erosion across four of the top five products — the entire debate compresses into that variable. The bear could still be right because management broke their own credibility 84 days after setting the FY26 guide, the FYA pull-forward of 2.5–3.5% of Q4 International revenue means the underlying organic line is weaker than the reported one, and the empirical industry erosion curve (Draxxin −66%, Rimadyl −39%) is real. The verdict flips to Lean Long with conviction if U.S. companion-animal organic growth (constant FX) returns to flat-or-positive in Q2 OR Q3 FY26 and the FY26 guide holds through year-end; it flips to Avoid if a second consecutive negative U.S. companion-animal organic print arrives, OR operating margin breaks below 35% under LOE drag, OR FY26 guidance is cut a second time. Durable thesis breaker: operating margin breaking below 35% (the moat itself is compressing, not just digesting one event). Near-term evidence marker: Q2 FY26 U.S. companion-animal organic growth print — the first read on whether the −11% was bounded or contagious.